HEAD-TO-HEAD

KISSPEPTIN-10 VS PT-141

Kisspeptin-10 and PT-141 are the two most-asked sexual-function research peptides, but they act at completely different layers of the CNS-endocrine axis. Kisspeptin-10 acts upstream on the HPG-axis (GPR54 / KISS1R → GnRH → LH/FSH → gonadal steroids). PT-141 (bremelanotide) acts centrally on melanocortin MC3/MC4 receptors in the hypothalamus to drive arousal pathways (dopamine + oxytocin). One is endocrine; the other is neuro-arousal.

A · No. 025

KISSPEPTIN-10

HPG Axis Trigger

B · No. 022

PT-141

Bremelanotide · MC4R Agonist · FDA Approved

SIDE BY SIDE

FIELD

A · KISSPEPTIN-10

B · PT-141

Class

Synthetic kisspeptin C-terminal active fragment (10 aa)

Cyclic melanocortin 3/4 receptor agonist (7 aa)

Sequence

Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂

Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Mechanism layer

Upstream HPG-axis · GnRH neuron firing

Central CNS · MC3/MC4 hypothalamic arousal

Half-life

Very short (minutes) plasma

~2.7 hours (subcutaneous)

Best evidence

Dhillo 2005 PMID 15883247 (LH/FSH pulse in healthy men) · Abbara IVF Phase 2 with kisspeptin-54

RECONNECT-1 / RECONNECT-2 Phase 3 · FDA-approved Vyleesi 2019 PMID 31022173

FDA status

Not FDA-approved · research-use only

FDA-approved as Vyleesi for HSDD in premenopausal women (June 2019)

Research focus

Reproductive endocrinology · IVF · hypogonadotropic hypogonadism

HSDD · sexual desire research · ED (Phase 2)

WADA status

Not specifically named; GnRH-axis status falls under S2 regulator discretion

Not currently listed (2026)

WHICH IS BETTER · BY GOAL

▶ FDA-approved sexual-function compoundB · PT-141

PT-141 (bremelanotide) is FDA-approved as Vyleesi for HSDD in premenopausal women (June 2019). Kisspeptin-10 is research-use only.

▶ HPG-axis / endogenous steroid researchA · KISSPEPTIN-10

Kisspeptin-10 is the canonical upstream activator of GnRH-axis. Single SC doses produce LH/FSH pulses (Dhillo 2005). PT-141 does not engage the HPG-axis directly.

▶ IVF / oocyte-maturation researchA · KISSPEPTIN-10

Kisspeptin (the 54-aa form specifically) has Phase 2 data as an oocyte-maturation trigger in IVF (Abbara 2014/2017). PT-141 not used in this context.

▶ Central arousal / desire researchB · PT-141

PT-141 has the RECONNECT Phase 3 program showing improvement in FSFI desire score · the primary endpoint for HSDD approval. Kisspeptin-10's link to sexual function is via downstream sex hormones, not central arousal directly.

STACKING NOTE

Kisspeptin-10 and PT-141 act on different systems (endocrine vs central arousal) and are not commonly co-administered in published research. Both are used as standalone compounds within their respective categories.

SOURCED FROM GIGACOMPOUNDS

Both compounds are available as research-grade material at GigaCompounds · ≥99% purity · per-batch CoA. For laboratory research use only.

SOURCE AT GIGACOMPOUNDS ▶